A coalition of congressional lawmakers sent a letter to President Joe Biden on Wednesday, urging him to reopen certain deportation cases, including those involving marijuana.
Rep. Mondaire Jones (D-NY) led the letter, which was signed by 30 members of the Congressional Black Caucus and is also addressed to Homeland Security Secretary Alejandro Mayorkas. It emphasizes that deportations disproportionately impact people of color and implores the president to use his authority to create a process through which these cases can be reevaluated and reversed.
“We are grateful for President Biden’s commitment to redressing racial injustice, particularly after the last four years of the Trump Administration’s racist and xenophobic immigration agenda,” it says. “One critical step toward honoring that commitment is ensuring that people who were unjustly deported can be fairly and efficiently considered for return to their families and communities in the United States.”
The lawmakers cite a number of examples of deportation cases that they feel unjustly harmed immigrants.
The letter asks Biden and U.S. Department of Homeland Security (DHS) to “consider the stories of U.S. veteran Howard Bailey and long-time U.S. resident Kenault Lawrence,” both of whom were deported to Jamaica over “years-old marijuana convictions.”
“Howard served nearly four years in the U.S. Navy, including two tours in Operation Desert Storm, and received the National Defense Service Medal. Nevertheless, he was deported based on an old, first-time marijuana offense that the governor of Virginia subsequently pardoned,” the Black Caucus members wrote. “Kenault’s deportation robbed him of the chance to meet his newborn child, merely three months prior to a U.S. Supreme Court ruling finding his ground of deportation to be unlawful.”
“Despite these clear injustices and the compelling reasons to return both men to the United States, neither Howard nor Kenault have a meaningful chance to return home,” the letter states. “They remain in exile in Jamaica.”
Bailey’s case also caught the attention of three U.S. senators who similarly sent a letter to the DHS head last week, asking the agency to reopen a case for the military veteran.
Bailey was arrested after a package containing marijuana was sent to his house for a friend and he pled guilty, on the advice of counsel. He disclosed the conviction when later applying for citizenship, and Immigration and Customs Enforcement (ICE) used that single cannabis offense as basis to initiate a deportation proceeding.
In the new House letter, the coalition said these are only a few examples of “the many people who have been unjustly deported.”
“Untold numbers of others have been similarly wronged, from U.S. veterans who served their country to longstanding neighbors who found themselves deported because of contact with the U.S. criminal legal system—a system acknowledged to unfairly and disproportionately target and discriminate against Black and brown people,” they wrote.
“We urge you to utilize your broad legal authority to return everyone unjustly deported, including Paul, Howard, and Kenault,” the letter continues. “We further ask that you establish a centralized process for exercising your discretion to evaluate and authorize returns going forward.”
Reps. Barbara Lee (D-CA), Hakeem Jeffries (D-NY), Gregory Meeks (D-NY), Eleanor Holmes Norton (D-DC), Karen Bass (D-CA), Ilhan Omar (D-MN), Ayanna Pressley (D-MA), Bonnie Watson Coleman (D-NJ) and Jamaal Bowman (D-NY) were among the signatories.
“For decades, the U.S. government has exercised its power by enforcing U.S. civil immigration laws aggressively—initiating removals, detaining immigrants, and conducting deportation proceedings that lack even minimal due process,” it says. “Now is the time to turn the resources and power of the U.S. government toward repairing these harms in the name of racial justice for Black and brown immigrants.”
In a spending bill moving through the House Appropriations Committee that allocates fiscal year 2022 funding for DHS, there’s a provision that would prevent its component agencies from denying any person immigration benefits or protections, or penalizing them in an application, simply because they’ve admitted to using cannabis or were convicted of a low-level marijuana offense.
According to the U.S. Citizenship and Immigration Services (USCIS), a person who admits to using cannabis—even in compliance with state law—is morally unfit for citizenship. The agency clarified that position in a 2019 memo, adding that employment in a state-legal marijuana market is another factor that could impact a person’s immigration status.
Standalone legislation has been introduced this session to resolve the problem, but it has yet to be acted on.
DHS did issue a memo in May that specifically encourages ICE attorneys to join motions to reopen immigration cases under circumstances where “an individual is eligible for relief under the law and merits relief as a matter of discretion.”
Read the letter to Biden and DHS on deportation cases involving marijuana below:
Photo courtesy of Philip Steffan.
Virginia Has Sealed 64,000 Marijuana Distribution Charges Since Legalization Took Effect This Summer
“These aren’t just numbers and there are families attached.”
By Ned Oliver, Virginia Mercury
Virginia has sealed records documenting more than 64,000 misdemeanor marijuana distribution charges since the state legalized the drug in July.
The figure came out Thursday during a meeting of the legislature’s Cannabis Oversight Commission.
Officials said the records were scrubbed from the state’s criminal record database, which is used by employers like school boards, state agencies and local governments to screen employees.
The state had already sealed 333,000 records detailing charges of simple possession last year after the state reduced the offense to a civil infraction on par with a traffic offense, said Shawn G. Talmadge, the Deputy Secretary of Public Safety and Homeland Security.
Lawmakers directed the state to expand that effort when they voted to broadly legalize recreational use of marijuana earlier this year.
The legislature also agreed to a broader expungement reform that will automatically seal other misdemeanor charges, including underage possession of alcohol, use of a fake ID, petit larceny, trespassing and disorderly conduct. Talmadge said those charges will remain in the system until the state finishes updating the software it uses to track criminal records.
“As of right now, the process is proceeding,” he said.
The Virginia Joint Commission on Cannabis Oversight is meeting now. You can find the agenda and links to livestream and to provide public comment at https://t.co/f1wsPn7SV7
— Jennifer McClellan (@JennMcClellanVA) October 14, 2021
Members of the oversight commission also heard from two advocates who urged them to move fast to address people currently imprisoned for marijuana offenses—a category of people the legalization legislation passed this year did not address.
Chelsea Higgs Wise, the leader of the advocacy group Marijuana Justice, and Gracie Burger, with the Last Prisoner Project, said Department of Corrections data suggests there are currently 10 people being held solely on serious marijuana charges.
They said it remains unknown how many more are being held because of marijuana related probation violations.
“These aren’t just numbers and there are families attached,” Burger said.
DEA Proposes Dramatic Increase In Marijuana And Psychedelic Production In 2022, Calling For 6,300 Percent More MDMA Alone
The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year.
In a notice scheduled to be published in the Federal Register on Monday, the agency said there’s been a “significant increase in the use of schedule I hallucinogenic controlled substances for research and clinical trial purposes,” and it wants authorized manufacturers to meet that growing demand.
DEA had already massively upped its proposed 2021 quota for cannabis and psilocybin last month, but now it’s calling for significantly larger quantities of research-grade marijuana and a broader array of psychedelics to be manufactured in 2022.
It wants to double the amount of marijuana extracts, psilocybin and psilocyn, quadruple mescaline and quintuple DMT. What especially stands out in the notice is MDMA. The agency is proposing an enormous 6,300 percent boost in the production of that drug—from just 50 grams in 2021 to 3,200 grams in the coming year—as research into its therapeutic potential continues to expand.
LSD would see a 1,150 percent increase, up to 500 grams of the potent psychedelic.
Marijuana itself would get a 60 percent boost under DEA’s proposal, up to 3.2 million grams in 2022 from the 2 million grams last year.
Here’s a visualization of the proposed quota increase from 2021 to 2022 for marijuana and cannabis extracts:
For all other THC, psilocybin, psilocyn and MDMA:
And for other psychedelic substances like LSD, mescaline and DMT:
DEA said in the Federal Register notice that it has been receiving and approving additional applications to “grow, synthesize, extract, and manufacture dosage forms containing specific schedule I hallucinogenic substances for clinical trial purposes” to achieve these ambitious quotas.
“DEA supports regulated research with schedule I controlled substances, as evidenced by increases proposed for 2022 as compared with aggregate production quotas for these substances in 2021,” the agency said, adding that it working “diligently” to process and approve marijuana manufacturers applications in particular, as there’s currently only one farm at the University of Mississippi that’s permitted to cultivate the plant for research.
“Based on the increase in research and clinical trial applications, DEA has proposed increases in 3,4- Methylenedioxyamphetamine (MDA), 3,4-Methylenedioxymethamphetamine (MDMA), 5-Methoxy-N,N-dimethyltryptamine, Dimethyltryptamine, Lysergic acid diethylamide (LSD), Marihuana, Marihuana Extract, Mescaline, Psilocybin, Psilocyn, and All Other Tetrahydrocannabinols to support manufacturing activities related to the increased level of research and clinical trials with these schedule I controlled substances.”
Here are the exact numbers for the proposed 2021 and 2022 quotas:
|All other tetrahydrocannabinol||1,000||2,000|
A 30-day public comment period will be open after the notice is formally published on Monday.
It’s difficult to overstate just how significant the proposed 2022 increases are, but it’s certainly true that scientific and public interest in marijuana and psychedelics has rapidly increased, with early clinical trials signaling that such substances show significant therapeutic potential.
National Institute on Drug Abuse (NIDA) Director Nora Volkow told Marijuana Moment in a recent interview that she was encouraged by DEA’s previous proposed increase in drug production quota. She also said that studies demonstrating the therapeutic benefits of psychedelics could be leading more people to experiment with substances like psilocybin.
Advocates and experts remain frustrated that these plants and fungi remain in the strictest federal drug category in the first place, especially considering the existing research that shows their medical value for certain conditions.
A federal appeals court in August dismissed a petition to require the DEA to reevaluate cannabis’s scheduling under the Controlled Substances Act. However, one judge did say in a concurring opinion that the agency may soon be forced to consider a policy change anyway based on a misinterpretation of the therapeutic value of marijuana.
Separately, the Washington State attorney general’s office and lawyers representing cancer patients recently urged a federal appeals panel to push for a DEA policy change to allow people in end-of-life care to access psilocybin under state and federal right-to-try laws.
Image element courtesy of Kristie Gianopulos.
Supreme Court Won’t Hear Case On Legalizing Safe Drug Consumption Sites, But Activists Are Undeterred
The U.S. Supreme Court (SCOTUS) has rejected a request to hear a case on the legality of establishing safe injection sites where people can use illicit drugs in a medically supervised environment.
The justices announced on Tuesday that they decided against taking up the case raised by the nonprofit Safehouse, despite the pleas of attorneys general from 10 states and D.C. who recently filed amici briefs urging the court’s involvement.
Representatives from 14 cities and counties, as well as the mayor of Philadelphia, which is at the center of the current case, also filed briefs in support of the case in recent days.
Safehouse was set to launch a safe consumption site in Philadelphia before being blocked by a legal challenge from the Trump administration. It filed a petition with the nation’s highest court in August to hear the case.
But while the Supreme Court declined to take action—and the Biden administration passed up its voluntary opportunity to weigh in at this stage, which may well have influenced the justices’ decision—activists say the battle will continue at a lower federal court level, where the administration will have to file briefs revealing its position on the issue.
Disappointed but not surprised U.S. Supreme Court declined to hear our case. We’re pursuing our claims in federal court. As that litigation proceeds, Biden administration will have to take a position, which it avoided by waiving its right to respond to our Supreme Court petition.
— Safehouse (@SafehousePhilly) October 13, 2021
“We were disappointed that the government chose not to respond to our petition,” Safehouse Vice President Ronda Goldfein told Filter. “They said, ‘We’re going to waive our right to respond,’ [and] the Supreme Court declined to review our case. Ordinarily that sounds like the end of the road—but in our case we are still pursuing our claims in a different venue.”
That venue will be the the federal district court in Philadelphia, where activists plan to submit multiple arguments related to religious freedom and interstate commerce protections. The Biden administration will be compelled to file a response in that court by November 5.
“If they don’t respond, they lose,” Goldfein said.
A coalition of 80 current and former prosecutors and law enforcement officials—including one who is President Joe Biden’s pick for U.S. attorney of Massachusetts—previously filed a brief urging the Supreme Court to take up Safehouse’s safe injection case.
Fair and Justice Prosecution, the group that coordinated the amicus brief, also organized a tour of Portugal for 20 top prosecutors in 2019 so they could learn about the successful implementation of the country’s drug decriminalization law.
If the Supreme Court were to have taken the case and rule in favor of Safehouse, it could have emboldened advocates and lawmakers across the country to pursue the harm reduction policy.
The governor of Rhode Island signed a bill in July to establish a safe consumption site pilot program where people could test and use currently illicit drugs in a medically supervised environment. It became the first state in the country to legalize the harm reduction centers. It’s not clear whether the Department of Justice will seek to intervene to prevent the opening of such facilities in that state.
Massachusetts lawmakers advanced similar legislation last year, but it was not ultimately enacted.
A similar harm reduction bill in California, sponsored by Sen. Scott Wiener (D), was approved in the state Senate in April, but further action has been delayed until 2022.